AVITA Medical, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparative period is Q1 2023. AVITA is a commercial-stage regenerative medicine company whose portfolio includes the RECELL System for burn wounds, full-thickness skin defects and vitiligo repigmentation. Amounts below are in U.S. dollars.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior balance | Change or context |
|---|---|---|---|
| Revenue | $11.1 million | $10.6 million | Up 5.3%; commercial sales were $11.07 million, including $10.96 million from RECELL and $0.11 million from other wound-care products. |
| Gross profit / margin | $9.6 million / 86.4% | $8.9 million / 84.2% | Margin improved, which management attributed mainly to higher revenue and lower shipping costs. |
| Operating expenses | $26.8 million | $19.4 million | Up 38.0%; sales and marketing rose to $12.6 million, G&A to $9.0 million and R&D to $5.2 million. |
| Operating loss | $17.2 million | $9.9 million | Loss widened as operating expenses increased and prior-year BARDA income of $0.6 million did not recur. |
| Net loss / loss per share | $18.7 million / $0.73 | $9.2 million / $0.37 | Net loss more than doubled; Q1 2024 included $1.36 million of interest expense, versus $4,000 in Q1 2023. |
| Operating cash flow | $(20.9) million | $(9.1) million | Cash use increased, with management citing higher operating costs and inventory purchases under the Stedical agreement. |
| Cash and cash equivalents | $17.0 million | $22.1 million at Dec. 31, 2023 | Decreased $5.2 million during the quarter. |
| Marketable securities | $51.2 million | $66.9 million at Dec. 31, 2023 | Cash plus marketable securities totaled $68.2 million at quarter-end. |
| Debt | $41.3 million fair-value carrying amount | $39.8 million at Dec. 31, 2023 | $40.0 million principal outstanding; secured facility bears 13.33% interest at March 31, 2024. |
| Total assets / stockholders’ equity | $97.4 million / $32.6 million | $111.6 million / $49.1 million at Dec. 31, 2023 | Equity declined, primarily reflecting the quarterly net loss. |
Material changes and developments
- U.S. revenue was $10.53 million, up from $9.43 million; Japan revenue declined to $0.46 million from $1.02 million. Management said commercial growth mainly reflected deeper customer penetration and new full-thickness skin-defect accounts.
- Sales and marketing costs increased 93%, primarily due to expansion of the sales force, related salaries and benefits, commissions, travel and professional fees. R&D spending rose 13%, while development expenses for RECELL GO were lower as the project entered a later development phase.
- The company began an exclusive U.S. distribution arrangement for PermeaDerm in January 2024. Its 2024 minimum purchase commitment is $5.0 million; $2.6 million had been purchased and approximately $2.4 million remained at quarter-end. This commitment is not recorded as a balance-sheet liability.
- AVITA extended its BARDA contract through September 28, 2025. BARDA will pay approximately $333,000 in maintenance fees for first access to RECELL inventory; no additional inventory build is required under the modification.
- The Ventura production-facility lease was extended, increasing operating lease assets and liabilities. Plant and equipment increased to $4.3 million, including construction in progress largely related to facility renovations and RECELL GO manufacturing materials.
Liquidity, outlook and risks
- Management stated it believes available cash reserves are sufficient to fund operations for the next 12 months and expects to use reserves until U.S. product sales support ongoing operations. Operating cash use was $20.9 million in the quarter; the filing provides no specific revenue or earnings guidance.
- The OrbiMed senior secured facility provides for up to $90 million: $40 million was drawn, with two potential $25 million tranches subject to revenue requirements. The first additional tranche is available at the company’s discretion through December 31, 2024; the second through June 30, 2025, subject to conditions. The company reported compliance with financial covenants and said projected trailing-12-month revenue through December 31, 2024 exceeded the applicable minimum.
- The credit agreement requires at least $10 million of unrestricted cash and cash equivalents and includes revenue thresholds that can trigger quarterly principal repayments, as well as customary default provisions and restrictions. Debt is secured by substantially all company and guarantor assets.
- Management reported that its February 28, 2024 response to the FDA’s additional-information request returned the RECELL GO application to the review cycle, with 90 days remaining. The filing projected approval and launch on May 31, 2024; this was a forward-looking expectation, not an approval reported in this filing.
- The company aims to expand RECELL adoption, launch RECELL GO following FDA approval, pursue RECELL GO mini, and expand internationally. It said an initial phase of U.S. commercial payor coverage for vitiligo was expected during Q4 2025.
- Risks highlighted include macroeconomic and geopolitical uncertainty, inflation, supply-chain and labor pressures, changes in hospital budgets and reimbursement, and the possibility that actual results differ from forward-looking statements. The company reported no material change to previously disclosed risk factors and no pending litigation believed likely to have a material adverse effect.
Important facts for investors to verify
- Whether revenue growth and deeper account penetration continue, especially in the U.S., and whether RECELL GO receives FDA approval and launches on the expected timetable.
- Whether cash burn moderates as sales expand, and how management’s 12-month liquidity assessment compares with actual cash and marketable-securities balances over subsequent quarters.
- Compliance with the $10 million unrestricted-cash covenant and revenue tests, the availability and conditions of additional OrbiMed tranches, and the cost of 13.33% debt.
- PermeaDerm sales, gross-margin realization and fulfillment of the remaining approximately $2.4 million 2024 minimum purchase commitment.
- The drivers and sustainability of the sharp increase in sales and marketing expense, and the impact of the company’s growth investments on operating losses.